Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Biodesix, Inc.. (9/15/16). "Press Release: Biodesix’ Nicholas Dupuis, Ph. D, Speaking at MSACL 3rd Annual Conference". Salzburg.

Region Region Salzburg
  Country Austria
Organisations Organisation Biodesix Inc.
  Organisation 2 MSACL Inc. (Association for Mass Spectrometry Applications to the Clinical Lab)
Products Product clinical mass spectrometry-based proteomic test
  Product 2 MSACL 2016 EU Salzburg

Biodesix’ Nicholas Dupuis, Ph. D, Speaking at MSACL 3rd Annual Conference: “Active Control of MALDI TOF Mass Spectra Acquisition With Internal Standards for Improved Quantitative Serum Protein Profiles”

Nicholas Dupuis, Ph.D, of Biodesix®, Inc. is speaking today at the MSACL 3rd Annual Conference, where he is the chairperson of the Protein Quantitation track. Dupuis is a Senior Scientist at Biodesix, where he leads technology transfer and assay development for proteomic products using Biodesix’ proprietary mass spectrometry based assays.

Where: Papageno Hall, Salzburg Congress Center

When: 11:15 AM

Short Abstract:

Matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) mass spectrometry (MS) is a rapid, reproducible, and sensitive tool for measuring protein profiles in biological fluids. Profiling has many potential clinical applications, including diagnosis, predicting disease aggressiveness, and assessing differential therapeutic benefit for cancer patients. In this study we: 1) incorporate multiple internal standards to allow quantitative comparisons between samples and 2) use a proportional-integral-derivative (PID) control algorithm to optimize spectral quality during acquisition. This approach expands the potential applications of MALDI profiling, markedly enhances spectral quality, and reduces reliance on operator intervention during acquisition.

Dr. Dupuis’ long abstract is also available

About Biodesix

Biodesix® is a molecular diagnostics company advancing the development of innovative blood tests in oncology to enable precision medicine. Biodesix discovers, develops and commercializes multivariate protein and genomic diagnostic blood tests, including the GeneStrat™ and VeriStrat® tests, that deliver results within 72 hours. The company is changing the standard of care by providing physicians with diagnostic tests for better therapeutic guidance, more accurate prognosis and enhanced disease monitoring to improve patient outcomes. At the forefront of precision medicine, Biodesix is developing new blood tests to identify patients who may benefit from immunotherapies. In addition to developing novel diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics for use with therapeutic agents.

Record changed: 2016-10-11


Picture [iito] No Tracking 650x80px

More documents for Biodesix Inc.

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture BIO Deutschland German Corona Special 2021 Digital 650x80px

» top